Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

Major Program
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
SWOG Cancer Research Network
Recruiting ID
For more information, see NCT05455606
This clinical trial studies how well an educationally enhanced genomic tumor board (EGTB)
intervention works to increase the number of patients with solid tumors that have come back
(recurrent), do not respond to treatment (refractory), have spread to other parts of the body
(metastatic), or are newly diagnosed and spread to other parts of the body (advanced) who
receive genome-informed treatment. Genome-informed treatment refers to treatment based on the
information found in genomic tumor test results. This study compares the usual approach to
reviewing genomic tumor test results with the approach of having a genomic tumor board (GTB)
review the test results. A GTB is team of doctors and scientists that have experience in
understanding genomic changes and review genomic tumor test results. The tumor board helps to
suggest whether there are other cancer treatment options based on patient genetic test
results. The usual approach is to review genomic tumor test results without the GTB being
involved. This study may help researchers learn if using a GTB enhances the treatment
decision making process within 6 months of joining the study. This study may also help
researchers learn if using the GTB increases doctors' understanding of genomic tumor test
results and increases doctors' comfort level with genomic tumor tests.
Best Practice, Chart Abstraction, Educational Intervention, Genomic Profile, Interview, Questionnaire Administration, Tumor Board Review
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Jens Rueter

See list of participating sites